Literature DB >> 16876135

Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims.

Félicien Karege1, Nader Perroud, Sandra Burkhardt, Michèle Schwald, Eladia Ballmann, Romano La Harpe, Alain Malafosse.   

Abstract

BACKGROUND: Past studies in the neurobiology of suicide have reported alterations in serotonin and downstream effectors, such as Akt/protein kinase B. In this study, we aimed to examine possible abnormality in the Akt/glycogen synthase kinase-3beta (GSK-3beta) axis of depressed suicide victims' brains.
METHODS: Twenty suicide victims and 20 drug-free non-suicide subjects were included for a postmortem study. The ventral prefrontal cortex area (BA'11) was used, and antemortem diagnoses of major depression disorder (MDD) (DSM-IV) were made from Institution's records. The protein levels of GSK-3alpha/beta and Akt-1 were assayed with the Western blot method, and the kinase activity of Akt and GSK-3alpha/beta were determined by phosphorylation of specific substrates.
RESULTS: There was no change either in GSK-3alpha/beta and Akt-1 protein levels or in lithium-inhibitable total GSK-3alpha/beta enzyme activity of the ventral prefrontal cortex. The enzyme activity of Akt decreased significantly [analysis of variance (ANOVA): F(3,36)=5.372; p= .003], whereas GSK-3beta activity increased significantly [ANOVA: F(3,36)=8.567; p= .002] in depressed suicide victims and non-suicide subjects but not in non-depressed suicide victims.
CONCLUSIONS: This study indicated that the activity rather than the protein levels of Akt and GSK-3beta was altered. The alteration was associated with MDD rather than with suicide per se.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16876135     DOI: 10.1016/j.biopsych.2006.04.036

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  81 in total

1.  The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder.

Authors:  Courtney S Jernigan; Dharmendra B Goswami; Mark C Austin; Abiye H Iyo; Agata Chandran; Craig A Stockmeier; Beata Karolewicz
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-05-23       Impact factor: 5.067

2.  Insulin reveals Akt signaling as a novel regulator of norepinephrine transporter trafficking and norepinephrine homeostasis.

Authors:  Sabrina D Robertson; Heinrich J G Matthies; W Anthony Owens; Vidiya Sathananthan; Nicole S Bibus Christianson; J Phillip Kennedy; Craig W Lindsley; Lynette C Daws; Aurelio Galli
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

Review 3.  Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments.

Authors:  George Bartzokis
Journal:  Neuropharmacology       Date:  2012-01-28       Impact factor: 5.250

4.  Antidepressant efficacy of a selective organic cation transporter blocker in a mouse model of depression.

Authors:  Alejandro Orrico-Sanchez; Laetitia Chausset-Boissarie; Rodolphe Alves de Sousa; Basile Coutens; Sara Rezai Amin; Vincent Vialou; Franck Louis; Assia Hessani; Patrick M Dansette; Teodoro Zornoza; Carole Gruszczynski; Bruno Giros; Bruno P Guiard; Francine Acher; Nicolas Pietrancosta; Sophie Gautron
Journal:  Mol Psychiatry       Date:  2019-10-16       Impact factor: 15.992

5.  Ciliary neurotrophic factor signaling in the rat orbitofrontal cortex ameliorates stress-induced deficits in reversal learning.

Authors:  Milena Girotti; Jeri D Silva; Christina M George; David A Morilak
Journal:  Neuropharmacology       Date:  2019-09-22       Impact factor: 5.250

6.  FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder.

Authors:  Katarzyna A Ellsworth; Irene Moon; Bruce W Eckloff; Brooke L Fridley; Gregory D Jenkins; Anthony Batzler; Joanna M Biernacka; Ryan Abo; Abra Brisbin; Yuan Ji; Scott Hebbring; Eric D Wieben; David A Mrazek; Richard M Weinshilboum; Liewei Wang
Journal:  Pharmacogenet Genomics       Date:  2013-03       Impact factor: 2.089

Review 7.  Regulation of inflammation and T cells by glycogen synthase kinase-3: links to mood disorders.

Authors:  Eleonore Beurel
Journal:  Neuroimmunomodulation       Date:  2014-02-14       Impact factor: 2.492

8.  Radiosynthesis and evaluation of [11C]CMP, a high affinity GSK3 ligand.

Authors:  Jaya Prabhakaran; Kiran Kumar Solingapuram Sai; Anirudh Sattiraju; Akiva Mintz; J John Mann; J S Dileep Kumar
Journal:  Bioorg Med Chem Lett       Date:  2019-01-25       Impact factor: 2.823

9.  Early effects of mood stabilizers on the Akt/GSK-3beta signaling pathway and on cell survival and proliferation.

Authors:  Jean-Michel Aubry; Michèle Schwald; Eladia Ballmann; Félicien Karege
Journal:  Psychopharmacology (Berl)       Date:  2009-05-14       Impact factor: 4.530

Review 10.  New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs.

Authors:  Zuleide M Ignácio; Gislaine Z Réus; Camila O Arent; Helena M Abelaira; Meagan R Pitcher; João Quevedo
Journal:  Br J Clin Pharmacol       Date:  2016-01-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.